-
Alcohol-related liver disease: A global perspective Ann. Hepatol. (IF 3.8) Pub Date : 2024-04-04 Graciela Elia Castro Narro, Luis Antonio Díaz, Eric Kauffman Ortega, María Fernanda Bautista Garín, Eira Cerda Reyes, Pindaro Sebastian Martinez Delfin, Juan Pablo Arab, Ramón Bataller
Alcohol-associated liver disease (ALD) represents one of the deadliest yet preventable consequences of excessive alcohol use. It represents 5.1 % of the global burden of disease, mainly involving the productive-age population (15-44 years) and leading to an increased mortality risk from traffic road injuries, suicide, violence, cardiovascular disease, neoplasms, and liver disease, among others, accounting
-
Liver rupture in patients with amyloidosis: Clinical features and treatment Ann. Hepatol. (IF 3.8) Pub Date : 2024-04-04 Xiangyu Du, Liangzhi Wen, Bin Wang, Dongfeng Chen, Wei Wang
-
Pathophysiology of Ascites: The importance of the intestine. A surgical contribution to the understanding of a medical problem Ann. Hepatol. (IF 3.8) Pub Date : 2024-03-11 Gabriel E. Gondolesi, Carolina Rumbo, Leonardo Montes, Lucia Novellis, Diego Ramisch, Ariel Riquelme Henríquez, Mariana Ortega, Federico Viano, Thomas Schiano, Valeria Descalzi, Claudio Tiribelli, Mihai Oltean, Pablo Barros-Schelotto, Héctor Solar
The understanding of the mechanisms for the development of ascites has evolved over the years, involving the liver, peritoneum, heart, and kidneys as key responsible for its formation. In this article, we review the pathophysiology of ascites formation, introducing the role of the intestine as a major responsible for ascites production through “a game changer” case.
-
Clinical, biochemical and histological features related to treatment response and prognosis in autoimmune hepatitis Ann. Hepatol. (IF 3.8) Pub Date : 2024-03-07 Ludmila Resende Guedes, Guilherme Grossi Lopes Cançado, Bruno Campos Santos, Luma dos Santos Jacomassi, Mateus Jorge Nardelli, Fernanda Maria Farage Osório, Luciana Costa Faria, Cláudia Alves Couto
Autoimmune hepatitis (AIH) is a rare disease with a complex and not fully understood pathogenesis. Prognostic factors that might influence treatment response, relapse rates, and transplant-free survival are not well established. This study investigates clinical and biochemical markers associated with response to immunosuppression in patients with AIH. This retrospective cohort study included 101 patients
-
Neurofilament light chain but not glial fibrillary acidic protein is a potential biomarker of overt hepatic encephalopathy in patients with cirrhosis Ann. Hepatol. (IF 3.8) Pub Date : 2024-03-07 Koos de Wit, Diederick J. van Doorn, Bregje Mol, Lonneke A. van Vught, Frederik Nevens, Ulrich Beuers, Cyriel Y. Ponsioen, Charlotte E. Teunissen, R. Bart Takkenberg
Hepatic encephalopathy (HE) is a frequent complication of cirrhosis and may cause cerebral damage. Neurodegenerative diseases can induce the release of neuroproteins like neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in body fluids, including blood plasma. We investigated whether NfL and GFAP could serve as potential diagnostic plasma biomarkers for overt HE (oHE). We included
-
Efficacy and safety of terlipressin and albumin vs. noradrenaline and albumin in adult patients with hepatorenal syndrome: A systematic review and meta-analysis Ann. Hepatol. (IF 3.8) Pub Date : 2024-03-07 Adnan Malik, Muhammad Imran Malik, Shahbaz Qureshi, Abdul Nadir
Hepatorenal syndrome (HRS) is a serious complication of cirrhosis treated with several medications. We want to evaluate terlipressin and albumin's effectiveness and safety compared to albumin and noradrenaline in adult hepatorenal disease patients. Clinical trials from four databases were included. Cochrane's approach for calculating bias risk was utilized. We rated the quality evaluation by Grading
-
Outcomes of liver transplantation for hepatocellular carcinoma in donation after circulatory death compared with donation after brain death: A systematic review and meta-analysis Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-27 Abdulahad Abdulrab Mohammed Al-Ameri, Shusen Zheng
Due to organ shortages, liver transplantation (LT) using donation-after-circulatory-death (DCD) grafts has become more common. There is limited and conflicting evidence on LT outcomes using DCD grafts compared to those using donation-after-brain death (DBD) grafts for patients with hepatocellular carcinoma (HCC). We aimed to summarize the current evidence on the outcomes of DCD-LT and DBD-LT in patients
-
Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-25 Mary Nemer, Fauzia Osman, Adnan Said
Our objective was to measure and compare the intake of macro and micronutrients in a cohort of individuals with Metabolic Syndrome Associated Steatotic Liver Disease (MASLD) compared with matched controls to identify areas of further research in this area; we identified nutrition-associated associations with MASLD in the United States general population. We used the 2017 – 2018 NHANES dataset. Elastography
-
MASLD identifies patients with significant hepatic fibrosis and steatosis in fatty liver population Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-23 You Deng, Wenya Chen, Wen Xie
-
Impact of new fatty liver disease nomenclature on primary care— cerebration of gastroenterologists in a regional tertiary care hospital Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-23 Xingcen Chen, Deliang Liu, Rong Li
-
Prevalence and mortality prognosis of steatotic liver disease phenotypes Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-23 Zhiyu Sun, Chi Zhou, Yiwen Zhang, Pengfei Li, Junjie Guo, Zhexun Lian, Hongwei Ji
-
Gradual dosing of ursodeoxycholic acid in mothers with intrahepatic cholestasis of pregnancy may improve composite neonatal outcome Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-23 Amir Hamud, Matan J. Cohen, Drorith Hochner-Celnikier, Benjamin Bar-Oz, Zvi Ackerman
Intrahepatic cholestasis of pregnancy (ICP) is often accompanied by fetal and maternal complications. Retrospective review of the clinical course of women with ICP and their neonates treated at our medical center over a 10-year period. Special attention was paid to the maternal and neonatal response to 2 different modes of ursodeoxycholic acid (UDCA) administration. Neonates of mothers with high total
-
Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-23 Ana Barreira-Díaz, Mar Riveiro-Barciela, Eva María Fernández-Bonilla, Vanesa Bernal, Agustín Castiella, Marta Casado-Martín, Carolina Delgado, María-Carlota Londoño, Álvaro Díaz-González, Indhira Pérez-Medrano, Andrés Conthe, Margarita Sala, Beatriz Mateos, Judith Gómez-Camarero, Dolores Antón-Conejero, Carmen Del Pozo-Calzada, Francisca Cuenca, Ares Villagrasa-Vilella, Magdalena Salcedo
Different patterns of liver injury have been reported in association with the SARS-CoV-2 vaccines. The aim of this study was to describe a nationwide cohort of patients with SARS CoV-2 vaccine-induced liver injury, focusing on treatment and the evolution after further booster administration. multicentre, retrospective-prospective study, including subjects who developed abnormal liver tests within 90
-
Correspondence: "A multisociety Delphi consensus statement on new fatty liver disease nomenclature." Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-23 Kim Sui Wan, Wah-Kheong Chan, Muhammad Fadhli Mohd Yusoff, Feisul Mustapha, Halizah Mat Rifin, Kishwen Kanna Yoga Ratnam, Noor Ani Ahmad
-
Psoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis? Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-14 Luciana Agoglia, Ana Carolina Cardoso, Lívia Barbosa, Cecília Schubert Xavier Lagalhard Victer, Sueli Carneiro, Paulo Henrique Condeixa de França, Maria Chiara Chindamo, Cristiane Alves Villela-Nogueira
A high prevalence of steatotic liver disease has been described in psoriasis. However, the influence of genetic polymorphisms has yet to be investigated in this scenario. This study aims to determine the frequency of steatosis, advanced liver fibrosis and PNPLA3/TM6SF2 genotypes in individuals with psoriasis and to evaluate the impact of genetic polymorphisms, metabolic parameters and cumulative methotrexate
-
Retinopathy as a predictive indicator for significant hepatic fibrosis according to T2DM status: A cross-sectional study based on the National Health and Nutrition Examination Survey Data. Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-12 Jinze Li, Yi Xiang, Jiahao Han, Youfang Gao, Ruiying Wang, Zihe Dong, Huihui Chen, Ruixia Gao, Chuan Liu, Gao-Jun Teng, Xiaolong Qi
Type 2 Diabetes Mellitus (T2DM), a prevalent metabolic disorder, often coexists with a range of complications, with retinopathy being particularly common. Recent studies have shed light on a potential connection between diabetic retinopathy (DR) and hepatic fibrosis, indicating a possible shared pathophysiological foundation in T2DM. This study investigates the correlation between retinopathy and hepatic
-
Occult liver disease: a multinational perspective Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-12 Paulina Vidal-Cevallos, Nayelli Flores-García, Norberto C. Chávez-Tapia, Naga P. Chalasani
Occult liver disease refers to the presence of unrecognized chronic liver disease and cirrhosis. Liver disease is currently the eleventh cause of death globally, representing 4% of all deaths in the world. Alcohol consumption is the leading cause of cirrhosis globally, accounting for approximately 60% of cases. The estimated global prevalence of non-alcoholic fatty liver disease (NAFLD) is 32.4% and
-
-
The 2023 Meeting of the Latin American Association for the Study of the Liver: A summary and looking ahead. Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-08 Francisco Javier Valentin-Cortez, Norberto Chávez-Tapia
-
ZBP1 promotes hepatocyte pyroptosis in acute liver injury by regulating the PGAM5/ROS pathway Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-06 Shengguang Yan, Lina Yu, Ziren Chen, Dan Xie, Zuli Huang, Shi Ouyang
Acute liver injury (ALI) is characterized by massive hepatocyte death with high mortality and poor prognosis. Hepatocyte pyroptosis plays a key role in the physiopathological processes of ALI, which can damage mitochondria and release NLRP3 inflammasome particles, causing systemic inflammatory responses. Z-DNA Binding Protein 1 (ZBP1) is a sensor that induces cell death. Here, we investigated whether
-
Impact of preoperative nonselective beta-blocker use on acute kidney injury after living donor liver transplantation: Propensity score analysis Ann. Hepatol. (IF 3.8) Pub Date : 2024-02-06 Hye-Won Jeong, Jae Hwan Kim, Sang-bin Han, Hye-Mee Kwon, In-Gu Jun, Jun-Gol Song, Gyu-Sam Hwang
Acute kidney injury (AKI) is prevalent and has deleterious effects on postoperative outcomes following liver transplantation (LT). The impact of nonselective beta-blockers (NSBBs) in patients with liver cirrhosis remains controversial. This study investigated the association between preoperative NSBB use and AKI after living donor LT (LDLT). We evaluated 2,972 adult LDLT recipients between January
-
The importance of fundamental pharmacology in fighting liver diseases Ann. Hepatol. (IF 3.8) Pub Date : 2024-01-22 Eduardo E. Vargas-Pozada, Erika Ramos-Tovar, Pablo Muriel
Abstract not available
-
Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysis Ann. Hepatol. (IF 3.8) Pub Date : 2024-01-24 Wasit Wongtrakul, Natthinee Charatcharoenwitthaya, Phunchai Charatcharoenwitthaya
Introduction and Objectives Cohort studies reported controversial results regarding the long-term prognosis of patients with lean non-alcoholic fatty liver disease (NAFLD) compared to non-lean NAFLD patients. This updated meta-analysis aimed to estimate the magnitude of the association between lean body mass index and all-cause mortality risk in NAFLD patients. Materials and Methods We systematically
-
Societal costs and survival of patients with biopsy-verified non-alcoholic steatohepatitis: Danish nationwide register-based study Ann. Hepatol. (IF 3.8) Pub Date : 2024-01-23 Jan Håkon Rudolfsen, Lise Lotte Gluud, Henning Grønbæk, Majken K. Jensen, Mogens Vyberg, Jens Olsen, Peter Bo Poulsen, Nanna Hovelsø, Nikolaj Ture Gregersen, Anne Bloch Thomsen, Peter Jepsen
Introduction and Objectives Studies on the societal burden of patients with biopsy-confirmed non-alcoholic fatty liver disease (NAFLD) are sparse. This study examined this question, comparing NAFLD with matched reference groups. Materials and Methods Nationwide Danish healthcare registers were used to include all patients (≥18 years) diagnosed with biopsy-verified NAFLD (1997–2021). Patients were classified
-
Development and validation of a noninvasive prediction model for significant hepatic liver fibrosis in Chinese patients with autoimmune hepatitis Ann. Hepatol. (IF 3.8) Pub Date : 2024-01-22 Hanzhu Chen, Wenya Ren, Xingdi Yang, Piao Hu, Shouhao Wang, Chengan Xu, Fei Lv, Yue Zhao, Qiaoqiao Yin, Wei Zheng, Jing Xu, Hongying Pan
Introduction and Objectives Autoimmune hepatitis (AIH) is a prevalent noninfectious liver disease. However, there is currently a lack of noninvasive tests appropriate for evaluating liver fibrosis in AIH patients. The objective of this study was to develop and validate a predictive model for noninvasive assessment of significant liver fibrosis (S ≥ 2) in patients to provide a reliable method for evaluating
-
Optimal ALT threshold for the automated diagnosis of MASLD: a population-based study using iLFT Ann. Hepatol. (IF 3.8) Pub Date : 2024-01-14 Jeremy Lee, Christopher J. Byrne, Paul N. Brennan, Iain MacPherson, Eleanor Dow, John F. Dillon
Introduction and Objectives : Early diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD), especially with advanced fibrosis, is crucial due to increased risk of complications and mortality. Serum alanine aminotransferase (ALT) is commonly used; however, many patients have normal ranges (<55 U/L) who may remain undetected. We investigated the clinical implications of a lower
-
Influence of socioeconomic factors on liver transplant survival outcomes in patients with autoimmune liver disease in the United States Ann. Hepatol. (IF 3.8) Pub Date : 2023-12-25 Leandro Sierra, Ana Marenco-Flores, Romelia Barba, Daniela Goyes, Bryan Ferrigno, Wilfor Diaz, Esli Medina-Morales, Behnam Saberi, Vilas R Patwardhan, Alan Bonder
Introduction and Objectives Autoimmune liver diseases (AILDs): autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) have different survival outcomes after liver transplant (LT). Outcomes are influenced by factors including disease burden, medical comorbidities, and socioeconomic variables. Materials and Methods Using the United Network for Organ Sharing
-
From NAFLD to MASLD: Promise and pitfalls of a new definition Ann. Hepatol. (IF 3.8) Pub Date : 2023-12-19 Kenneth Cusi, Zobair Younossi, Michael Roden
Abstract not available
-
Reply to: “From NAFLD to MASLD: Promise and pitfalls of a new definition’ Ann. Hepatol. (IF 3.8) Pub Date : 2023-12-19 Mary E. Rinella, Graciela E.Castro Narro, Aleksander Krag, Norah Terrault, Philip N. Newsome
Abstract not available
-
From NAFLD to MASLD: When metabolic comorbidity matters Ann. Hepatol. (IF 3.8) Pub Date : 2023-12-21 Shan Hong, Lei Sun, Yiwei Hao, Ping Li, Yuling Zhou, Xiuxia Liang, Julong Hu, Hongshan Wei
-
A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease Ann. Hepatol. (IF 3.8) Pub Date : 2023-12-20 Maria Jimenez Ramos, Timothy J. Kendall, Ignat Drozdov, Jonathan A. Fallowfield
Metabolic dysfunction-associated steatotic liver disease (MASLD), defined by the presence of liver steatosis together with at least one out of five cardiometabolic factors, is the most common cause of chronic liver disease worldwide, affecting around one in three people. Yet the clinical presentation of MASLD and the risk of progression to cirrhosis and adverse clinical outcomes is highly variable
-
Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha Ⅴ promotes invasion and metastasis of cholangiocarcinoma cells Ann. Hepatol. (IF 3.8) Pub Date : 2023-12-18 Shuguang Pan, Ying Hu, Lang Gan, Jiejuan Lai, Ping Zheng, YuJun Zhang, Ling Shuai, Yan Jiang, Mo Chen, Junping Wang, Yu He
Introduction and Objectives Cholangiocarcinoma (CCA) is characterized by early distant invasion and metastasis, whereas the underlying mechanism is still obscure. Increasing evidence shows that collagen type Ι alpha 1 (COL1A1) is a gene associated with the progression of multiple diseases. Here, we attempted to investigate the role of COL1A1 in CCA. Materials and Methods The expression of COL1A1 between
-
From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America. Ann. Hepatol. (IF 3.8) Pub Date : 2023-12-01 Federico Piñero, Ezequiel Mauro, Paola Casciato, Alejandro Forner
The most common primary liver tumors are hepatocellular carcinoma and cholangiocarcinoma. They constitute the sixth most common neoplasia and the third cause of cancer-related deaths worldwide. Although both tumors may share etiologic factors, diagnosis, prognostic factors, and treatments, they differ substantially in determining distinctive clinical management. In recent years, significant advances
-
Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents Ann. Hepatol. (IF 3.8) Pub Date : 2023-12-01 Andrea del Carmen Maldonado-Rojas, Julia María Zuarth-Vázquez, Misael Uribe, Varenka J Barbero-Becerra
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by overweight/obesity, and the presence of type 2 diabetes mellitus is the most important criterion. We propose an independent disease perspective without exclusion criteria and with less heterogeneity and greater impact because, according to the National Health and Nutrition Survey (ENSANUT), in Mexico, 25 % of adults
-
MiR-326 sponges TET2 triggering imbalance of Th17/Treg differentiation to exacerbate pyroptosis of hepatocytes in concanavalin A-induced autoimmune hepatitis Ann. Hepatol. (IF 3.8) Pub Date : 2023-12-01 Genglin Zhang, Sensen Wu, Guangtao Xia
Introduction and Objectives MicroRNA-326 is abnormally expressed in autoimmune diseases, but its roles in autoimmune hepatitis (AIH) are unknown. In this study, we aimed to investigate the effect of miR-326 on AIH and the underlying mechanism. Materials and Methods Concanavalin A was administrated to induce AIH in mice and the expression levels of miR-326 and TET2 was evaluated by qRT-PCR and western
-
A practical approach to the endoscopic management of biliary strictures after liver transplantation Ann. Hepatol. (IF 3.8) Pub Date : 2023-11-28 Alex Bofill, Andrés Cárdenas
Biliary tract complications are an important cause of morbidity and mortality after liver transplantation (LT) occurring in 5 % to 25 % of patients. The most common biliary complication in LT recipients are strictures representing approximately half of these biliary adverse events. Bile duct strictures can be divided into anastomotic biliary strictures (ABS) and non-anastomotic biliary strictures (NABS)
-
Performance of eight predictive models for hepatocellular carcinoma recurrence after liver transplantation: a comparative study Ann. Hepatol. (IF 3.8) Pub Date : 2023-11-24 Ajacio Bandeira de Mello Brandão, Santiago Rodriguez, Cláudio Augusto Marroni, Alfeu de Medeiros Fleck Junior, Matheus V. Fernandes, Marcos Mucenic
-
Evolving portal hypertension through Baveno VII recommendations Ann. Hepatol. (IF 3.8) Pub Date : 2023-11-19 Manuel Mendizabal, Guilherme Grossi Lopes Cançado, Agustín Albillos
The Baveno VII consensus workshop has provided several novel recommendations regarding the management of patients with clinically significant portal hypertension (CSPH). The expert panel summarized the existing data into simple clinical rules to aid clinicians in their clinical practice. The use of non-invasive tests (NITs), especially liver stiffness measurement (LSM), have gain an important role
-
Assessment of TLL1 variant and risk of hepatocellular carcinoma in Latin Americans and Europeans Ann. Hepatol. (IF 3.8) Pub Date : 2023-11-20 Siyu Fu, Dhamina Karim, Jhon Prieto, Domingo Balderramo, Javier Diaz Ferrer, Angelo Z. Mattos, Marco Arrese, Enrique Carrera, Jeffrey Oliveira, Jose D. Debes, Andre Boonstra
Introduction and Objectives Tolloid like protein 1 (TLL1) rs17047200 has been reported to be associated with HCC development and liver fibrosis. However, to our knowledge, no studies have been performed on Latin Americans and comparative differences between TLL1 rs17047200 in HCC patients from Latin America and Europe are undefined. Materials and Methods Cross-sectional analysis performed on Latin
-
Liquid biopsy: New opportunities for precision medicine in hepatocellular carcinoma care Ann. Hepatol. (IF 3.8) Pub Date : 2023-11-14 Inah Marie C. Aquino, Devis Pascut
Liquid biopsy, specifically the analysis of circulating tumor DNA (ctDNA) offers a non-invasive approach for hepatocellular carcinoma (HCC) diagnosis and management. However, its implementation in the clinical setting is difficult due to challenges such as low ctDNA yield and difficulty in understanding the mutation signals from background noise. This review highlights the crucial role of artificial
-
The burden of liver disease in Latin America Ann. Hepatol. (IF 3.8) Pub Date : 2023-11-03 Luis Antonio Díaz, Marcela Villota-Rivas, Francisco Barrera, Jeffrey V. Lazarus, Marco Arrese
Liver disease poses a substantial burden in Latin America. This burden is primarily attributed to a high level of alcohol consumption and the increasing prevalence of risk factors associated with metabolic dysfunction-associated steatotic liver disease (MASLD), such as sedentary lifestyles, easy access to ultra-processed foods, obesity, and type 2 diabetes mellitus. These epidemiological trends are
-
Non-linear associations of circulating total bilirubin concentration with the risk of nonalcoholic fatty liver disease and all-cause mortality Ann. Hepatol. (IF 3.8) Pub Date : 2023-11-03 Hui Han, Qingtao Yu, Nina Qin, Bin Song, Yan Meng, Zuojing Feng, Zhaoping Li, Liyong Chen
Introduction and Objectives Accumulating evidence has supported that mild elevated total bilirubin exerts antioxidant and anti-inflammatory properties in multiple metabolic diseases. We aimed to explore the association of circulating total bilirubin concentration with non-alcoholic fatty liver disease (NAFLD) risk and all-cause mortality and examine the potential nonlinear relationships between them
-
Administration of Silymarin in NAFLD/NASH: A systematic review and meta-analysis Ann. Hepatol. (IF 3.8) Pub Date : 2023-10-29 Shudi Li, Fei Duan, Suling Li, Baoping Lu
-
Trajectories of patients relisted for liver transplantation. Ann. Hepatol. (IF 3.8) Pub Date : 2023-10-18 Fakhar Ali Qazi Arisar, Rhea Varghese, Shiyi Chen, Wei Xu, Markus Selzner, Ian McGilvray, Blayne Sayed, Trevor Reichman, Chaya Ganor Shwaartz, Mark Cattral, Anand Ghanekar, Gonzalo Sapisochin, Elmar Jaeckel, Cynthia Tsien, Nazia Selzner, Leslie Lilly, Mamatha Bhat
Introduction and Objectives : Recurrent cirrhosis complicates 10-30% of Liver transplants (LT) and can lead to consideration for re-transplantation. We evaluated the trajectories of relisted versus primary listed patients on the waitlist using a competing risk framework. Materials and Methods : We retrospectively examined 1,912 patients listed for LT at our centre between from 2012 to 2020. Cox proportional
-
Alcohol-associated liver disease: epidemiology and management. Ann. Hepatol. (IF 3.8) Pub Date : 2023-10-12 Helena Hernández-Évole, Natalia Jiménez-Esquivel, Elisa Pose, Ramón Bataller
Alcohol is the leading cause of preventable morbidity and mortality worldwide, as it is also the most frequent cause of liver disease. Alcohol-associated liver disease (ALD) covers different phenotypes ranging from steatosis to the development of inflammation (steatohepatitis), fibrosis and ultimately, in a proportion of patients, the development of liver cirrhosis and its associated complications
-
Surgical resection versus transcatheter arterial chemoembolization for large hepatocellular carcinoma: A deeper insight Ann. Hepatol. (IF 3.8) Pub Date : 2023-10-10 Aimen Waqar Khan, Sarah Waqar Khan
Abstract not available
-
The landscape of inpatient admissions for alcoholic hepatitis in the era of early liver transplantation Ann. Hepatol. (IF 3.8) Pub Date : 2023-10-08 Shahana Prakash, Tomohiro Tanaka
Introduction and Objectives Liver transplant (LT) is a recent option available in the United States (US) to treat those with severe, refractory alcoholic hepatitis (AH). We examined changes in clinical characteristics of patients admitted with AH and tracked hospital outcomes as practice changes involving LT have shifted. Materials and Methods Using the National Inpatient Sample, we performed a cross-sectional
-
A clinical review of congenital hepatic fibrosis diagnosed in adulthood: presentation, complications, and outcomes Ann. Hepatol. (IF 3.8) Pub Date : 2023-10-04 Lauren Loeb, Jason Lewis, Zhongwei Peng, Michael G. Heckman, Raouf Nakhleh, Andrew P. Keaveny
Introduction and Objectives Congenital hepatic fibrosis (CHF) is a rare condition characterized by biliary tract changes and a geographic pattern of liver fibrosis. Liver biopsy is essential to confirm its diagnosis. The absence of specific clinical indicators in adults often leads to delays in diagnosis and management, while the natural history has not been well described. We sought to define the
-
Prognostic value of lactate/albumin ratio in patients with acute-on-chronic liver failure Ann. Hepatol. (IF 3.8) Pub Date : 2023-10-04 Yalcin Golcuk, Burcu Kaymak Golcuk
Abstract not available
-
Balancing perspectives: Schistosomiasis in the liver disease landscape of the Philippines Ann. Hepatol. (IF 3.8) Pub Date : 2023-10-05 Eric David Ornos, Janus P. Ong
Abstract not available
-
Schistosomiasis: A neglected cause of liver disease in the Philippines Ann. Hepatol. (IF 3.8) Pub Date : 2023-10-05 Alexander M. Sy
Abstract not available
-
TCD assessment in fulminant hepatic failure: Improvements in cerebral autoregulation after liver transplantation Ann. Hepatol. (IF 3.8) Pub Date : 2023-10-04 Fernando M Paschoal-Jr, Ricardo C Nogueira, Karla de Almeida Lins Ronconi, Marcelo de Lima Oliveira, Kelson James Almeida, Ivana Schmidtbauer Rocha, Eric Homero Albuquerque Paschoal, Joelma Karin Sagica Fernandes Paschoal, Luiz Augusto Carneiro D'Albuquerque, Manoel Jacobsen Teixeira, Ronney B Panerai, Edson Bor-Seng-Shu
Introduction and Objectives Acute liver failure, also known as fulminant hepatic failure (FHF), includes a spectrum of clinical entities characterized by acute liver injury, severe hepatocellular dysfunction and hepatic encephalopathy. The objective of this study was to assess cerebral autoregulation (CA) in 25 patients (19 female) with FHF and to follow up seventeen of these patients before and after
-
Ending stigmatizing language in alcohol and liver disease: A liver societies' statement Ann. Hepatol. (IF 3.8) Pub Date : 2023-09-27
Abstract not available
-
Cavin1 activates the Wnt/β-catenin pathway to influence the proliferation and migration of hepatocellular carcinoma Ann. Hepatol. (IF 3.8) Pub Date : 2023-09-27 Xingyuan Hao, Jinghua Li, Bin Liu, Wei Jing, Yonghua Guo, Fusheng Liu, Xiaomian Li, Xi Chen, Yufeng Yuan, Weijie Ma
-
Prevalence of occult hepatitis B virus infection and characterisation of hepatitis B surface antigen mutants among adults in western Croatia Ann. Hepatol. (IF 3.8) Pub Date : 2023-09-25 Marina Bubonja-Šonje, Dolores Peruč, Maja Abram, Bojana Mohar-Vitezić
Introduction and Objectives Occult hepatitis B virus (HBV) infection (OBI) is characterised by low levels of hepatitis B virus (HBV) DNA in the blood/liver of patients with negative hepatitis B surface antigen (HBsAg). This study aimed to determine the OBI prevalence and virological characteristics (viral genotypes and HBsAg mutants) in patients with an “anti-HBc only” serological profile. Materials
-
Brushing your teeth may be good for your liver: Linking oral health to non-alcoholic fatty liver disease Ann. Hepatol. (IF 3.8) Pub Date : 2023-09-23 Yusuf Yilmaz
Abstract not available
-
Prevalence of post-liver transplant complications and NASH-related cirrhosis in postmenopausal women Ann. Hepatol. (IF 3.8) Pub Date : 2023-09-24 Natalia Salinas Parra, Michelle Schafer, Heather M. Ross, John Bruckbauer, Brian Yan, Sarah L. Chen, Adnan Khan, Danielle M. Tholey, Dina Halegoua-DeMarzio
Introduction and Objectives Compared to premenopausal women, postmenopausal women are at greater risk of developing NAFLD and NASH, two common indications for liver transplantation (LT). We aim to determine the prevalence of NASH-related cirrhosis in postmenopausal women from a cohort of LT patients and investigate their post-LT complications. Materials and Methods Chart review of 1200 LT patients
-
NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study Ann. Hepatol. (IF 3.8) Pub Date : 2023-09-24 Renling Yao, Sufang Lu, Ruifei Xue, Jian Wang, Yuanwang Qiu, Yuxin Chen, Jiacheng Liu, Li Zhu, Jie Zhan, Suling Jiang, Shengxia Yin, Xin Tong, Weimao Ding, Jie Li, Chuanwu Zhu, Rui Huang, Chao Wu
Introduction and Objectives Chronic hepatitis B (CHB) may progress to more serious liver diseases and it is often accompanied by non-alcoholic fatty liver disease (NAFLD). NAFLD and CHB share risk factors for liver fibrosis and cirrhosis, but the influence of NAFLD on fibrosis progression is controversial. This retrospective study evaluated the prevalence of NAFLD in patients with CHB and investigated
-
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: an updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018 Ann. Hepatol. (IF 3.8) Pub Date : 2023-09-22 Tongtong Wang, Yuzhi Xi, Annaswamy Raji, Michael Crutchlow, Gail Fernandes, Samuel S Engel, Xiao Zhang
Introduction and Objectives : Data on the prevalence of non-alcoholic fatty liver disease (NAFLD) in subgroups of the United States (US) population are limited. This study was conducted to estimate NAFLD prevalence overall and by subgroup, and prevalence of NAFLD with advanced fibrosis. Materials and Methods : Using the National Health and Nutrition Examination Survey (NHANES) 2011-2018 data, a cross-sectional
-
Global prevalence of occult HBV infection in children and adolescents: A systematic review and meta-analysis Ann. Hepatol. (IF 3.8) Pub Date : 2023-09-23 Jiaying Wu, Jiayao He, Hongmei Xu
Introduction and Objectives Occult HBV infection (OBI) is a specific form of hepatitis B virus (HBV) infection and has the possibility of developing into hepatocellular carcinoma (HCC) in adults. This study aimed to estimate the global prevalence of occult HBV infection in children and adolescents. Materials and Methods We systematically searched PubMed, Embase, Web of Science, and Cochrane databases